Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epristeride SCHEMBL23833504 | 1.00 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL16115063 | 1.00 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL5444493 | 1.00 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL9782857 | 0.99 | SRD5A2 (0.98) | SRD5A2SRD5A1 | |
| SCHEMBL9114229 | 0.93 | SRD5A2 (0.86) | SRD5A2SRD5A1 | |
| SCHEMBL8994092 | 0.91 | SRD5A2 (0.83) | SRD5A2SRD5A1 | |
| SCHEMBL8151553 | 0.91 | SRD5A2 (0.83) | SRD5A2SRD5A1 | |
| SCHEMBL8151554 | 0.91 | SRD5A2 (0.83) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL9782855 | 0.91 | SRD5A2 (0.83) | SRD5A2SRD5A1 | |
| SCHEMBL9391082 | 0.90 | SRD5A2 (0.82) | SRD5A2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10419 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250295634-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | RHODE ISLAND HOSPITAL | 2025-09-25 | — | — | US | claimed |
| US-20250281509-A1 | SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSTY | 2025-09-11 | — | — | US | claimed |
| EP-4608405-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Veradermics, Incorporated (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250262192-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | KONINKLIJKE PHILIPS N.V. (NL) | 2025-08-21 | — | — | US | claimed |
| US-20250075180-A1 | METHOD FOR EXPANSION CULTURE OF GAMMA-DELTA T CELL | IMMUNOMAX CO., LTD. (KR) | 2025-03-06 | — | — | US | claimed |
| EP-4499222-A2 | COMPOSITIONS AND METHODS FOR PROMOTING HAIR GROWTH | Locus Solutions IPCO, LLC (US) | 2025-02-05 | — | — | EP | claimed |
| CN-119320422-A | Eplerite impurity 17 beta- (N-tertiary butyl-amino-formyl) androstane-3, 5-diene-3-diphenyl phosphine oxide and preparation method and application thereof | 江苏联环药业股份有限公司 | 2025-01-17 | — | — | CN | claimed |
| WO-1995006461-A1 | STABILIZED TABLET FORMULATION | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-09 | — | — | WO | claimed |
| EP-0633892-A1 | N-T-BUTYL-ANDROST-3,5-DIENE-17$g(b)-CARBOXAMIDE-3-CARBOXYLIC ACID POLYMORPH A | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0633781-A1 | COMPOSITIONS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-18 | — | — | EP | claimed |
| WO-1994017663-A1 | TREATING ALOPECIA BY ADMINISTERING 5-ALPHA-REDUCTASE INHIBITING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-18 | — | — | WO | claimed |
| WO-1993019758-A1 | COMPOSITIONS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-14 | — | — | WO | claimed |
| WO-1993019080-A1 | N-T-BUTYL-ANDROST-3,5-DIENE-17β-CARBOXAMIDE-3-CARBOXYLIC ACID POLYMORPH B | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-30 | — | — | WO | claimed |
| WO-1993019081-A1 | N-T-BUTYL-ANDROST-3,5-DIENE-17β-CARBOXAMIDE-3-CARBOXYLIC ACID POLYMORPH A | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-30 | — | — | WO | claimed |
| EP-0289327-B1 | STEROID 5-ALPHA-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-12-18 | — | — | EP | claimed |
| US-5017568-A | Enzyme inhibitors, carboxylation | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-21 | — | — | US | claimed |
| EP-0289327-A2 | Steroid 5-alpha-reductase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1988-11-02 | — | — | EP | claimed |